Drug firm Cipla today said the US health regulator has issued four observations across its three manufacturing facilities in Goa after the inspection.
"United States Food and Drug Administration (USFDA) recently concluded audit of our three manufacturing facilities in Goa and has issued four observations across these three facilities," Cipla said in a filing to BSE.
These observations were primarily procedural in nature and the company has already responded to the same, it added.
The company, however, did not provide any details of the observations.
"We continue to operate our facilities with a high level of compliance and control," Cipla said.
The stock was trading at Rs 581.55 in the afternoon trade on BSE, down 3.22 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
